Carro · The Journal of neuroscience : the official journal of the Society for Neuroscience 2005 · Animal and mechanistic laboratory study · n=?

Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I.

Cited 225 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Animal and in vivo mechanistic laboratory study without human clinical data

PubMed 16306401 · doi:10.1523/JNEUROSCI.2909-05.2005 · record verified 2026-08-30

What was done

The authors evaluated the role of the choroid plexus receptor megalin (low-density lipoprotein receptor-related protein-2, LRP2) in mediating circulating insulin-like growth factor I (IGF-I) neuroprotective activity. They assessed choroid plexus megalin levels after physical exercise and in normal aged animals. They also used viral-directed overexpression and RNA interference to manipulate choroid plexus megalin levels in animal models of cognitive loss, measuring brain IGF-I transport, amyloid-beta clearance, tau hyperphosphorylation, and cognitive function.

What was found

Physical exercise increased choroid plexus megalin/LRP2 levels, whereas normal aging was associated with decreased megalin/LRP2. Overexpression and knockdown experiments demonstrated that megalin is necessary for IGF-I transport across the blood-brain interface and for IGF-I-stimulated amyloid-beta clearance. Megalin-dependent IGF-I action prevented tau hyperphosphorylation and preserved cognitive function in animal models of cognitive decline. The abstract reports no quantitative values or statistical effect sizes.

Why it matters

These findings identify choroid plexus megalin as a critical molecular conduit linking systemic exercise and circulating IGF-I to brain amyloid-beta clearance and tau regulation. The age-related loss of choroid plexus megalin offers a potential mechanistic explanation for reduced neuroprotective signaling and increased vulnerability to late-onset Alzheimer's disease.

Limits

The abstract provides no exact sample sizes, animal model details, intervention durations, or numerical data. All findings are derived from preclinical animal models and molecular manipulations, so direct applicability and therapeutic relevance to human Alzheimer's disease remain unverified.

Cited by